Identifying biomarkers from adverse events to predict lung cancer outcomes
Official title: Development of adverse event (AE) derived biomarkers for predicting clinical outcomes in lung cancer
Funded at H. Lee Moffitt Cancer Ctr & Res Inst · NIH-11010783 · Data updated 2026-11-12
This study is looking at how side effects from lung cancer treatments, like high blood pressure and immune reactions, can help us understand how well patients are doing and find better ways to tailor their treatments for safety and effectiveness.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | H. Lee Moffitt Cancer Ctr & Res Inst NIH-funded |
| Lab location | 1 site (Tampa, United States) |
| Project start | January 12, 2024 |
| Project end | December 31, 2025 |
| Funding year | 2025 |
| Award (this year) | $212,689 |
| NIH project number | 5R21CA286417-02 |
| Project ID | NIH-11010783 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are lung cancer patients undergoing chemotherapy who experience various adverse events during their treatment.
✕Less likely to help
Patients with lung cancer who do not experience any adverse events during treatment may not benefit from this research.
What this research studies
This research focuses on developing biomarkers derived from adverse events (AEs) experienced by lung cancer patients during treatment. By analyzing various AEs, such as hypertension and immune-related reactions, the study aims to create a more comprehensive understanding of how these events correlate with patient survival outcomes. The approach involves utilizing advanced methodologies to assess the severity, frequency, and duration of AEs, transforming traditional data into actionable biomarkers that can guide personalized treatment strategies. This innovative analysis seeks to enhance patient safety and improve the efficacy of lung cancer therapies.
Why it matters
Potential benefit: If successful, this research could lead to more accurate predictions of clinical outcomes for lung cancer patients, ultimately improving treatment strategies and patient safety.
How similar studies have gone: Previous studies have shown promising results in utilizing adverse event data to predict clinical outcomes, indicating that this approach has potential for success.
Where this research is happening
-
H. Lee Moffitt Cancer Ctr & Res Inst
Tampa, United States Active
Researchers
- Principal investigator: Chen, Dung-Tsa — H. Lee Moffitt Cancer Ctr & Res Inst
- Study coordinator: Chen, Dung-Tsa
Related research
Other NIH-funded projects on the same topics.
-
Blood-based markers to identify lung cancer risk in never-smokers
A researchers team at NYU School of Medicine is testing blood tests that might flag higher lung cancer risk in people who have never smoked, helping decide who might need screening.
-
Integrative Analysis of Lung Cancer Risk and Its Causes
A large, multi-part study at the University of New Mexico is exploring why lung cancer happens and how to better prevent and detect it.
-
Integrative Analysis of Lung Cancer Risk and Causes
A large NIH project is exploring how tobacco use, behavior, biology, and screening practices influence lung cancer risk and outcomes to help prevent and detect it earlier.
-
Digital health strategies to expand lung cancer screening in safety-net clinics
A funded project aims to help low-resource clinics increase the use of lung cancer screening for patients who smoke or are at risk.
-
Proteomics-guided matching of lung cancer tumors to preclinical models
This grant aims to improve how we match a patient’s lung cancer tumor to the right preclinical models using protein data.
-
Optimizing lung cancer care with smart tools for prevention, early detection, treatment, and survivorship
A U01 grant using AI and biomarkers to improve lung cancer prevention, screening, treatment, and survivorship care for people at risk or living with lung cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.